Clinical Trial Update: Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CC-486 with Nab-Paclitaxel vs Nab-Paclitaxel in chemotherapy-naïve metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• CC-486 (azacitidine)

Snippet

Sponsor: Celgene Corporation | Conditions: Metastatic Melanoma | Phase 2 | Status: WITHDRAWN